Interleukin-17 (IL-17), a cytokine produced by T helper 17 (Th17) cells, is a key player in host inflammation and immune dysfunction leading to autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis or asthma, among others.

Researchers from China Pharmaceutical University have reported the discovery of novel orally bioavailable fms-like tyrosine kinase 3 (FLT3) inhibitors as potential candidates for the treatment of acute myeloid leukemia (AML). Synthesis and optimization of a novel series of FLT3 inhibitors led to the identification of LT-540-717 as the lead candidate.

Researchers from University North Carolina, Chapel Hill have discovered prostate-specific member antigen (PSMA)-targeted agents with reduced salivary gland uptake while maintaining high tumor uptake. Synthesis and subsequent screening of PSMA agents bearing different chelators and targeting ligands led to the identification of two lead agents, NOTA-UNC-PSMA-2 and DOTA-UNC-PSMA-2.

It seems unlikely that American poet and civil rights activist Maya Angelou spent much time thinking about translational research. But two quotes of hers capture the essence of the interplay between bench and bedside: “I did then what I knew how to do. Now that I know better, I do better” and “I’ve learned that I still have a lot to learn.” At the 2023 Annual Congress of the European Academy of Neurology, Mary Reilly described the relationship between bench and bedside as “a continuous circle of translation,” with each cycle beginning with patients and their needs.

National Taiwan University researchers reported the identification of a novel sorafenib derivative, SCB-24, which has the potential to be a new antimicrobial therapeutic.